Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Iterum Therapeutics plc | itrm-ex991_6.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 30, 2020
|
Iterum Therapeutics plc |
||
|
(Exact name of registrant as specified in its charter) |
||
|
Ireland |
001-38503 |
98-1283148 |
|
(State or other jurisdiction |
(Commission File Number) |
(IRS Employer Identification No.) |
|
of incorporation) |
|
|
|
|
|
|
|
|
|
|
|
Block 2 Floor 3, Harcourt Centre, Harcourt Street, Dublin 2, Ireland |
Not applicable |
|
|
(Address of principal executive offices) |
(Zip Code) |
|
|
Registrant’s telephone number, including area code: +353 1 903 8920 |
||
|
|
||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12 (b) of the Act:
|
Title of Each Class |
Trading Symbol(s) |
Name of Each Exchange on Which Registered |
|
Ordinary Shares, par value $0.01 per share |
ITRM |
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 8.01. Other Events.
On September 30, 2020, Iterum Therapeutics plc, or the Company, issued a press release announcing that, based on discussions at a pre-NDA meeting with the U.S. Food and Drug Administration, it plans to proceed with an NDA submission for sulopenem etzadroxil/probenecid, a bilayer tablet, for the treatment of uncomplicated urinary tract infections in patients with a quinolone-resistant pathogen.
The full text of the press release issued in connection with this announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.Description
99.1 Press Release of Iterum Therapeutics plc dated September 30, 2020
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
Iterum Therapeutics plc |
||
|
|
|
|
||
|
Dated: September 30, 2020 |
|
|
||
|
|
|
By: |
/s/ Corey N. Fishman |
|
|
|
|
|
Corey N. Fishman |
|
|
|
|
|
Chief Executive Officer |
|